IONS
NasdaqGSIonis Pharmaceuticals, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 20 recent filings. 14 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Hayden Michael R Director | Buy (open market) | 15K | $53.38 | $800,700.00 | 2026-07-30 |
Hayden Michael R Director | Buy (open market) | 5K | $51.60 | $258,000.00 | 2026-07-31 |
Reikes Peter N Director | Grant / award | 3.4K | $0.00 | — | 2026-07-15 |
HANTSON LUDWIG Director | Grant / award | 3.4K | $0.00 | — | 2026-07-15 |
HERMAN JOAN E Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
HERMAN JOAN E Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
BERTHELSEN SPENCER R Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
BERTHELSEN SPENCER R Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
BENNETT C FRANK EVP, Chief Scientific Officer | Sell (open market) | 5.54K | $83.58 | $462,693.34 | 2026-07-07 |
BENNETT C FRANK EVP, Chief Scientific Officer | Code J | 15K | $0.00 | — | 2026-07-07 |
BENNETT C FRANK EVP, Chief Scientific Officer | Sell (open market) | 15K | $85.46 | $1,281,930.00 | 2026-07-07 |
BENNETT C FRANK EVP, Chief Scientific Officer | Code J | 15K | $0.00 | — | 2026-07-07 |
Diaz Allene M. Director | Option exercise | 10.11K | $47.11 | $476,329.21 | 2026-07-07 |
Diaz Allene M. Director | Sell (open market) | 10.11K | $85.42 | $863,637.13 | 2026-07-07 |
Diaz Allene M. Director | Option exercise | 10.11K | $0.00 | — | 2026-07-07 |
Kordasiewicz Holly B. EVP, Chief Development Officer | Sell (open market) | 362 | $84.30 | $30,516.60 | 2026-07-07 |
YANG MICHAEL J. Director | Grant / award | 5.37K | $0.00 | — | 2026-07-01 |
YANG MICHAEL J. Director | Grant / award | 2.3K | $0.00 | — | 2026-07-01 |
LOSCALZO JOSEPH Director | Grant / award | 5.37K | $0.00 | — | 2026-07-01 |
LOSCALZO JOSEPH Director | Grant / award | 2.3K | $0.00 | — | 2026-07-01 |
Source: SEC EDGAR Forms 4/4A (CIK 874015). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$IONS Why is it so quiet here? is it because majority of the shares owned by insiders/institutions?
$IONS Insider purchased $1.06 million worth of shares: https://filingtracker.ai/filing/874015/0000874015-26-000254
$IONS hell is wrong with this stock no chance of going up.
$IONS Will this recover to 60? I started doubting 55 now....
$BMY $GILD $IONS $RARE $REPL good luck 🍀
6/ $IONS — Sept 22, 2026 PDUFA for zilganersen in Alexander disease. Thesis: ultra-rare neuro catalyst with Priority Review + Breakthrough/Orphan/Rare Pediatric Disease designations; first-and-only treatment potential vs small-market launch execution.
1/ Biotech FDA catalysts I’m watching over the next ~60 days. Not investment advice — just a sourced watchlist. PDUFA dates can move, and binary FDA events can gap hard both ways. Sources are company IR/news releases. $REPL $BMY $RARE $GILD $IONS
$IONS earnings was very good. This will come around today and end bright green. Gl all.
$IONS your thoughts on earnings?
$IONS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.69 down -188.46% YoY • Reported revenue of $268M down -40.71% YoY • Ionis Pharmaceuticals remains on track to achieve its 2026 financial guidance, including full-year product sales targets for TRYNGOLZA and DAWNZERA, while maintaining its goal of cashflow breakeven in 2028.
$IONS right now sentiment is very negative, so a positive call could make it go up significantly. On the other hand a bad one would probably bring us to 50$ again, as per last week. We will know soon 😅
$IONS this is going to pull a KNSA-like move tomorrow with earnings. Gl all.
Latest news
Ionis Pharmaceuticals Insider Bought Shares Worth $1,058,700, According to a Recent SEC Filing
Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ...
Why Biogen Stock Is Resisting a Market Downturn After Earnings
Ionis Pharmaceuticals Q2 Earnings Call Highlights
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q2 Earnings: A Look at Key Metrics
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals: Q2 Earnings Snapshot
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.